Quick answer
What preclinical models have been used for sermorelin research? Sermorelin (GHRH 1-29 amide) appears in rat and pig endocrine studies mainly as the unmodified comparator for modified analogs. Rat studies show that timing and exposure pattern change the GH response, pig studies compare a PEGylated 1-29 amide with the unmodified one, and organ-level studies such as the perfused heart used GHRH rather than sermorelin.
"Preclinical research applications" is a phrase that invites sweeping claims. The published record is narrower and more interesting: a handful of well-designed models, each tied to a specific molecule, species and question. This article maps them, notes where sermorelin was actually used and where it was not, and flags the limits. For laboratory research use only; not for human consumption.
What "preclinical endocrinology" covers for a GHRH peptide
Preclinical work on GHRH peptides spans cell culture, isolated organs, rodent and large-animal endocrine models and genetic models. This article is a map of the in vivo and ex vivo end of that spectrum, with one rule: each result is stated for the molecule that was actually tested. Sermorelin is GHRH (1-29) amide, the 29-residue fragment of the 44-residue hormone; many studies used the native hormone, modified 1-29 analogs or other GHRH agonists, and sermorelin enters mostly as a comparator. The product page lists the compound's listed research applications (GHRH receptor signaling, somatotropic axis models and pulsatile GH-release studies), and the overview introduces the biology. Cell-level work is outside the scope here.
| Model level | Example system | Question it answers | Source |
|---|---|---|---|
| Isolated organ | Perfused rat heart under ischemia and reperfusion | Do GHRH receptors outside the pituitary mediate a direct effect? | Penna et al. [1] |
| Small-animal endocrine | Freely moving rats, repeated sampling | How does somatostatin tone shape the response to a GHRH peptide? | Tannenbaum and Ling [2] |
| Small-animal pattern study | Female rats, continuous versus pulsatile infusion | Does the pattern of exposure alter GH mRNA, stores and growth? | Borski et al. [3] |
| Large-animal | Pigs, intravenous and subcutaneous routes as reported | Do modified 1-29 peptides change GH and IGF-I responses? | D'Antonio et al. [4] |
| Genetic | "Little" mouse with a receptor point mutation | Is the receptor required for pituitary development? | Lin et al. [5] |
The pattern across the table is the useful finding. Each level answers a different question, and none can substitute for another; a perfused heart says nothing about GH secretion, and a pituitary culture says nothing about organ-level effects.
Rodent studies: timing and pattern
Two rat papers shape how every later experiment is designed. In freely moving rats, the GH response to hpGRF-44 or rat GRF depended on when in the ultradian GH rhythm the peptide was given: responses at the peak were significantly larger than at the trough, and removing endogenous somatostatin with a specific antiserum eliminated the difference and allowed marked release at trough [2]. The inference drawn by the authors was that GRF and somatostatin are both present tonically with a rhythmic surge of each. The second paper, in female rats, compared continuous GHRH infusions with pulsatile administration at a 1.5-hour frequency: continuous infusions did not alter GH mRNA, pituitary GH stores or weight gain, but pulsatile administration doubled GH mRNA, raised pituitary GH stores and increased body weight gain, and the authors concluded that pulsatile but not continuous GHRH induces GH mRNA and content as well as somatic growth in that model [3].
A third paper tested a long-acting GH-RH(1-30)NH2 analog by continuous and repeated administration and reported that low-dose continuous exposure sensitized the pituitary response while high-dose exposure desensitized it, a pattern also seen in superfusion experiments [6]. For a reader planning a rodent study, the three results converge: the endpoint depends on the exposure pattern and the time of day, and the identity of the peptide and its time course should be reported with the same care as its concentration. Studies of this kind report species, sex, route and schedule as part of the methods; the published values are not recommendations and are not reproduced here.
Large-animal work: pigs and PEGylated 1-29
Pigs are a standard large-animal model for the GH axis. In the pharmacodynamic study of a mono-PEGylated GRF(1-29)NH2 (a 5,000 Da PEG chain on Lys 12 or Lys 21), the analog was tested after a single intravenous administration in rats and after a single intravenous or subcutaneous administration in pigs. In pigs, intravenous GRF-1PEG(5000) increased the response of the endogenous GH peaks, and subcutaneous administration significantly raised both GH and IGF-I compared with placebo and with unmodified GRF(1-29)NH2 [4]. This is useful for two reasons. It shows that the unmodified 1-29 amide, which is sermorelin's sequence, is bioactive in a large-animal model, and it provides a direct side-by-side with the modified analog. The companion review notes that the Lys 12 and Lys 21 PEG isomers kept high receptor-level activity [7], which tells a designer that the middle of the molecule tolerates bulk better than the N-terminus. A related porcine study reported that [Ala15]-hGRF(1-29)NH2 raised GH release in cultured pituitary cells and decreased expression of the long-form leptin receptor [8].
Beyond the pituitary: extrapituitary receptors
The pituitary is not the only tissue with a GHRH receptor. A 2025 review of GHRH receptor signaling reports splice variants of the receptor in human neoplasms and other extrapituitary tissues, with splice variant 1, the closest to the full-length receptor, eliciting cAMP signaling and mitogenic activity on stimulation, and the same review surveys work on GHRH agonists and antagonists across oncology, endocrinology, cardiology, ophthalmology, inflammation, wound healing and other fields [9]. A 2024 pilot study of 15 pediatric hematological and oncological specimens examined mRNA for GHRH and for splice variant 1 by RT-PCR [10]. These are expression and mechanistic data in tissue specimens; they define where the receptor is found and do not establish function in a living system.
The perfused heart experiment is the clearest example of a direct tissue effect in an ex vivo model. Isolated rat hearts subjected to ischemia and reperfusion were given GHRH at the onset of reperfusion. GHRH reduced infarct size at the end of reperfusion and reversed contractility dysfunction, and these effects were blocked by the GHRH antagonist JV-1-36 and by inhibitors of the RISK and SAFE pathway components; the effect was attributed to receptor-mediated signaling that includes Akt, ERK1/2, GSK-3β and STAT3 phosphorylation [1]. For a research design, the implication is that a GHRH-receptor ligand can act on tissues without involving GH at all. A study that attributes every effect of a GHRH peptide as "through GH" is making an assumption the literature does not support.
What the models cannot say about sermorelin
Reading the literature critically, four limits are worth stating.
| Limit | Why it matters | Practical response |
|---|---|---|
| Molecule mismatch | Native 44-residue, 1-30 analogs, PEGylated and Ala15 peptides are not sermorelin | Cite the molecule tested; use sermorelin data only where sermorelin was tested |
| Species mismatch | Rat peptide and human peptide differ and the rat peptide is more potent in rats [2] | Match peptide origin to the species model |
| Pattern dependence | Continuous and pulsed exposure give opposite outcomes in rats [3][6] | Report exposure pattern with every result |
| Endpoint distance | GH is proximal; IGF-I and growth are distal and multi-source | Measure the proximal step and the distal step separately |
There is also a negative finding to keep in mind: there is no published demonstration, in the sources cited here, that sermorelin itself improves any organ-level outcome in a preclinical model. The perfused heart result used GHRH, not sermorelin. Wherever the sermorelin name appears in a search result next to an organ-level claim, trace the claim to the paper and read which molecule was used.
Matching the model to the question, and the material to the model
A short decision guide for planning:
- Receptor signaling question: use receptor-expressing cells and cAMP readouts, as in the overview.
- Pulsatility question: use a design that controls timing and somatostatin tone; compare with the long-acting analogs in pulsatile GH-axis design.
- Persistence question: compare with the long-acting analog in the CJC-1295 comparison first.
- Extrapituitary question: use a receptor antagonist control, as the heart study did with JV-1-36 [1].
Whatever the model, verify the material. A peptide whose identity and purity are unknown is a confound in every one of the studies above. How to read a COA, understanding HPLC purity and the COA library describe what to check, the calculator handles the volume arithmetic, and the shop lists related compounds including ipamorelin, which acts through the secretagogue receptor instead.
All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.
Frequently asked questions
What animal models have been used with GHRH peptides?
Freely moving rats, female rats on infusion schedules, pigs, isolated perfused rat hearts and genetic mouse models, each answering a different question.
Has sermorelin itself been tested in animals?
The unmodified GRF(1-29) amide has been used as the comparator in rat and pig studies of modified analogs. Many other studies used the native hormone or other analogs.
Why does time of day matter in rat studies?
GH secretion is rhythmic and somatostatin tone varies; in one study, removing somatostatin eliminated the difference between peak and trough responses.
Is pulsatile or continuous exposure more effective in rats?
In the female rat study cited, pulsatile but not continuous GHRH induced GH mRNA and content and weight gain.
Do GHRH receptors exist outside the pituitary?
Yes. Splice variants have been reported in neoplasms and other tissues, with splice variant 1 the closest to the full-length receptor.
What did the heart study show?
In isolated rat hearts, GHRH at reperfusion reduced infarct size and reversed contractile dysfunction, and an antagonist blocked it. It used GHRH, not sermorelin.
Does a PEGylated analog behave like sermorelin?
It is bioactive in similar assays but has a different pharmacodynamic profile, with a longer GH response in rats and pigs.
How should I cite a GHRH result for sermorelin?
Name the molecule actually tested in the paper and avoid generalizing from the family to sermorelin.
Related reading: Sermorelin Research Guide: Question Map and Sources, Sermorelin in 2026: What Recent Research Adds, Sermorelin Research Profile: Formula, Mass, Stability.
References
- Penna C, Settanni F, Tullio F, Trovato L, Pagliaro P, Alloatti G, et al. GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. Endocrinology. 2013;154(4):1624-35. doi:10.1210/en.2012-2064
- Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-7. doi:10.1210/endo-115-5-1952
- Borski RJ, Tsai W, Demott-Friberg R, Barkan AL. Induction of growth hormone (GH) mRNA by pulsatile GH-releasing hormone in rats is pattern specific. Am J Physiol Endocrinol Metab. 2000;278(5):E885-91. doi:10.1152/ajpendo.2000.278.5.E885
- D'Antonio M, Louveau I, Esposito P, Bertolino M, Canali S. Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs. Growth Horm IGF Res. 2004;14(3):226-34. doi:10.1016/j.ghir.2003.12.014
- Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature. 1993;364(6434):208-13. doi:10.1038/364208a0
- Kovács M, Fáncsik A, Mezö I, Teplán I, Flerkó B. Effects of continuous and repetitive administration of a potent analog of GH-RH(1-30)NH2 on the GH release in rats. Neuroendocrinology. 1994;59(4):371-9. doi:10.1159/000126680
- Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1279-91. doi:10.1016/s0169-409x(03)00109-1
- Lin J, Barb CR, Kraeling RR, Rampacek GB. Growth hormone releasing factor decreases long form leptin receptor expression in porcine anterior pituitary cells. Domest Anim Endocrinol. 2003;24(2):95-101. doi:10.1016/s0739-7240(02)00209-6
- Halmos G, Schally AV, et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025;26(3):343-352. doi:10.1007/s11154-025-09952-x
- Juhász É, Szabó Z, Schally AV, Király J, Fodor P, Kónya G, et al. Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in a Cohort of Hungarian Pediatric Patients with Hematological and Oncological Disorders: A Pilot Study. Int J Mol Sci. 2024;25(16):. doi:10.3390/ijms25168831
